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Abstract—Mitral regurgitation is one of the most common
forms of heart valve disorder, which may result in heart
failure. Due to the rapid ageing of the population, surgical
repair and replacement treatments, which have represented
an effective treatment in the past, are now unsuitable for
about half of symptomatic patients, who are judged high-
risk. Encouraged by the positive experience with transcath-
eter aortic valves and percutaneous reconstructive mitral
treatments, a number of research groups are currently
engaged in the development of minimally invasive
approaches for the functional replacement of the mitral
valve. The ﬁrst experiences have clearly demonstrated that
the approach is feasible and promising, though signiﬁcant
progress is still required in the prostheses design and
implantation procedures before the treatment can establish
as a safe and effective solution. This review analyses the
devices currently at a most advanced stage of development,
describing their main features and the technical solutions that
they adopt in order to respond to the functional requirements
of the most challenging of the heart valves.
Keywords—Mitral valve, Transcatheter heart valve replace-
ment, TAVI, TMVI.
INTRODUCTION
Mitral regurgitation (MR) is one of the most com-
mon forms of heart valve disorder, occurring when
blood leaks from the left ventricle into the left atrium.
This results from the failure of apposition of the mitral
valve leaﬂets, due to degenerative or functional causes.
Degenerative MR is associated with alterations of the
mitral valve leaﬂet structure, whereas functional MR
occurs due to changes in shape of the heart chambers
or damage to the heart muscle (e.g., from myocardial
infarction) resulting in annular dilatation and papillary
muscle displacement, which compromises correct
leaﬂet coaptation.
If untreated, MR results in increased afterload and
heart failure risk. It is estimated that symptomatic MR
aﬀects over four million Europeans and a similar
number of Americans29,36,42 and, due to the continu-
ous ageing of the western population, the number of
cases is expected to rise signiﬁcantly in the future. In
fact, MR prevalence increases with age, rising from
0.5% for young patients (18–44-year-old) to 9.3% for
patients older than 75 years.42,52 Therefore, a signiﬁ-
cant proportion of symptomatic patients are in their
late age, with relevant co-morbidities and previous
surgery.20,29,33,47 As a result, up to 50% of them are
currently declined for surgery because they are judged
too ill or weak to withstand the stress of the invasive
treatment.29,40,50
In recent years, the growing need for less invasive
therapeutic approaches has led to the development of a
number of reconstructive percutaneous treatments for
MR. However, these procedures mainly contribute to
alleviate the symptoms and are only suitable for very
speciﬁc forms of mitral valve disease and anatomic
subsets. The possibility to perform a complete percu-
taneous mitral valve replacement still represents an
unmet need, which would provide enormous advan-
tages for a vast and enlarging patients’ population.15,30
Transcatheter valve replacement has already been
successfully applied to the treatment of pulmonary and
aortic valves.22 However, despite the relevance of the
described clinical need, the application of this
approach to the mitral valve has been attempted only
recently, and is still in its infancy. This delay is justiﬁed
by the more severe technical challenges associated with
the geometry of the anatomical site and the more
critical loading conditions.
This review presents a technical description of the
most advanced solutions for percutaneous functional
replacement of the mitral valve that are currently
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reported in the literature. In particular, the alternative
approaches adopted to meet the functional require-
ments are analyzed and discussed, identifying the main
areas that still require improvement in order to trans-
form this disruptive technology into a sustainable
treatment.
PERCUTANEOUS MITRAL VALVE REPAIR
The ﬁrst percutaneous mitral valve procedure can be
dated back to the early 1980s, when Inoue and col-
leagues performed the ﬁrst balloon valvuloplasty for
treatment of mitral stenosis,28 accessing the valve
region via antegrade venous route (with transseptal
puncture). This approach has quickly become the
solution of choice for congenital stenotic mitral
valves8,39 in patients with isolated mitral stenosis and
suitable anatomy.53 However, this disease is now
uncommon in developed countries and the procedure
is not free from complications, including failure to
relieve stenosis, formation of MR and systemic
embolization.2,53 Mitral valve regurgitation represents
a much more common disease in the western world,14
which affects patients often untreatable surgi-
cally.29,40,50 Hence, a number of minimally invasive
procedures have recently been developed to target this
disease. These are essentially reconstructive treatments
(valve repair) that aim to improve the leaﬂets apposi-
tion by remodeling one of the functional substructures.
Below, they are classiﬁed based on the substructure
that they target to achieve their function.
Leaﬂets Plication Procedures
The main percutaneous approach currently adopted
for mitral repair is based on the edge-to-edge tech-
nique. This consists in the apposition of the central
portion of the anterior and posterior mitral valve
leaﬂets to create a double-oriﬁce valve with reduced
leaﬂet excursion and reduced regurgitation.1 This is
achieved by manipulating a grasping clip (MitraClip,
Abbott Vascular)12 or suturing device (Mobius,
Edwards).10,15 The main limitation of this procedure is
it being restricted to patients without severe dilatation
of mitral annulus, relatively normal leaﬂets, mitral
valve prolapse and central regurgitation.6 Moreover,
clinical results indicate the inability of the technique to
eliminate regurgitation in all patients.21 In fact, the
edge-to-edge technique was developed as an adjunct to
standard surgical repair procedures, and its use as a
stand-alone technique is still debated.6,13
In 2008 the Abbott’s MitraClip percutaneous repair
device obtained CE marking, followed by FDA
approval in 2013. This remains the only percutaneous
reconstructive device currently available on the mar-
ket.
Annulus Reshaping Procedures
Other popular approaches aim to restore the leaﬂets
coaptation by reshaping the mitral annulus. In the ﬁrst
solutions, this was achieved by implanting into the
coronary sinus a stent-like device (such as the Carillon,
Cardiac Dimensions and the Monarc, Edwards) that
forces the reshaping of the posterior region of the
annulus, producing an approximation of the mitral
valve leaﬂets.32,35 However, this approach is consider-
ably limited by the great anatomical variability of the
coronary sinus, and is not applicable in about half of
the patients. Lastly, the consequence of long-term
placement of such an aggressive prosthesis into
the coronary sinus, whose walls are very thin, is still
unknown and raises some concern.2,6,12
Other devices achieve the reduction of the antero-
posterior diameter by applying an epicardial pressure
that modiﬁes the shape of the left ventricle and, con-
sequently, the annulus. This is obtained by tethering
cords passed into the ventricle (iCoapsys, Myocor) or
inﬂating silicone bands placed around the atrioven-
tricular groove (BACE, Mardil).
Alternative recent methodologies replicate more
closely surgical annuloplasty, which achieve leaﬂet
coaptation by undersizing the annulus perimeter.
These are based on transannular or subannular cin-
ching by means of sutures that are anchored and
tethered (e.g., Mitralign System, Mitralign and Accu-
cinch System, Guided Delivery Systems), or by
anchored Dacron bands of adjustable length (Cardio-
band, Valtech). The main limitation of these
approaches is that they only allow partial cinching
(posterior leaﬂet only).10,26
Other solutions achieve the annulus undersizing
by shrinking its collagen ﬁbers with the heat gener-
ated by radio frequencies or ultrasound (e.g.,
QuantumCor Device, QuantumCor and ReCor
Device, ReCor Medical). The drawback of this
approach is the potential over-constriction or
undercorrection, as well as possible damage to the
surrounding structures.10 The long-term outcome for
these devices is still unknown, and their development
has been discontinued.
MINIMALLY INVASIVE HEART VALVE
FUNCTIONAL REPLACEMENTS
As described above, percutaneous repair treatments
generally only relieve the symptoms of very speciﬁc
forms of mitral valve disease and anatomic subset, and
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are still surpassed in eﬃcacy by surgical repair.25,38 A
minimally invasive mitral valve functional replacement
would allow the treatment of a broader spectrum of
patients, disease etiologies and anatomical variations,
with signiﬁcant beneﬁts for the substantial patient
population unable to undergo invasive surgery.15,30
This approach would reduce both the procedural and
recovery time for heart valve replacements,41 with
signiﬁcant potential for cost saving43 as well as more
accessible procedure both in terms of patient popula-
tions, pathologies and global location,11 surpassing the
relatively excessive risk factors and resource-intensive
requirements of conventional open heart surgical
replacements. Moreover, as shown in the case of the
pulmonary valve, they can represent an excellent
bridge treatment before surgery for children.
Pulmonary and Aortic Valve Experience
The ﬁrst human valve replacement using a percu-
taneous procedure was reported in 2000 by Professor
Philipp Bonhoeﬀer,9 who successfully implanted a
valved stent in the pulmonary artery prosthetic conduit
of a 12-year-old boy with stenosis and insufﬁciency.
The valve was an 18 mm bovine jugular vein valve,
sutured to a NuMed CP platinum-iridium stent. The
prosthesis received CE Mark approval in 2006 and
FDA approval under Humanitarian Device Exemp-
tion in 2010, and is now widely used.
The approach was soon adopted for the treatment
of the aortic valve, with the ﬁrst human implantation
described by Dr Alain Cribier and colleagues in
2002. They delivered a bovine pericardial valve sewn
into a stainless steel stent using a venous trans-septal
(antegrade) approach. The patient, who had been
judged to be too weak to withstand the stress of
open-heart surgery, was a 57-year-old man who had
presented in cardiogenic shock due to severe calciﬁc
aortic stenosis with a bicuspid aortic valve. Since
then, transcatheter aortic valve implantation (TAVI)
has established as the treatment of preference for
calciﬁed aortic valves in high risk patients.22,24,54
Two valve devices, the Edwards SAPIEN (a direct
evolution of the prosthesis implanted by Dr Cribier)
and the Medtronic CoreValve, have been in the
European market since 2007 (FDA approval was
granted in 2011 and 2014, respectively) and a num-
ber of second generation devices are already emerg-
ing.
Adaptation of Transcatheter Aortic Valve Implantation
Technology for the Mitral Position
Despite the pertinent clinical need,6,7 the translation
of transcatheter valve technologies to the mitral
position has been hindered by the need of alternative
engineering strategies, taking into account the complex
morphology of the valve, the higher transvalvular
pressure and the larger size of the required devices.48
Also, this application necessitates the adaptation of the
delivery and deployment methods, sizing algorithms,
intraprocedural imaging, failure modes and post pro-
cedural assessment parameters, all of which are unique
to the mitral position.
Main Devices Under Development and Structural
Components
A number of research groups and companies are
currently working on the adaptation of percutaneous
valve solutions speciﬁcally for the mitral position. In
this section, the transcatheter mitral valve implants
(TMVI) known at a most advanced stage of devel-
opment are described and discussed. These include:
 CardiAQ Prosthesis (CardiAQ Valve Technol-
ogies Inc., Winchester, Massachusetts, US)
 Cardiovalve (Valtech Cardio Ltd, Or Yehuda,
Israel)
 Double-Crowned Mitral Valve Implantation
(Zhejiang University, Hangzhou, China &
Centre Hospitalier Universitaire Vaudois
(CHUV), Lausanne, Switzerland)
 Endovalve (Micro Interventional Devices,
Langhorne, Pennsylvania, US)
 FORTIS (Edwards Lifesciences, California,
US)
 Gorman (The Trustees of The University of
Pennsylvania, Philadelphia, US)
 HighLife (HighLife Medical Inc., California,
US)
 Medtronic Transcatheter Mitral Valve (Med-
tronic Inc., Minneapolis, US)
 MitralSeal (Avalon Medical Ltd., Stillwater,
Minneapolis, US)
 MitrAssist (MitrAssist Medical Ltd, Misgav,
Israel)
 MiVAR (Trinity College Dublin, EIRE)
 NaviGate Cardiac Structures (NaviGate Car-
diac Structures Inc., Cleveland, Ohio, US)
 Tendyne (Tendyne Medical Inc., Baltimore,
Maryland, US)
 Tiara (NeoVasc Inc., Richmond, British
Columbia, Canada)
A schematic illustration of the devices and a
description of their main features are reported in
Table 1.
As in all prosthetic heart valves, in order to restore
unidirectional blood ﬂow through the cardiac cham-
bers, the devices are comprised of an occluding
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component, a supporting structure and a securing
means that avoids valve dehiscence. The presence of a
sealing component to minimize paravalvular leakage is
also preferable, especially for mitral valve applications.
The occluding component of all described solutions
consist of three membrane leaﬂets (apart from the
MitrAssist which has two asymmetrical leaﬂets) made
from glutaraldehyde ﬁxed bovine or porcine pericar-
dium, sewn onto a supporting frame. This functional
solution is optimal for percutaneous valves because the
ﬂexibility of the membranes allows them to be folded
easily. Moreover, membrane valves can operate in
different conﬁgurations, accommodating the speciﬁc
anatomical shapes and dimensions. This feature offers
the possibility to adapt the valve to an implantation
site whose dimensions and tissue elasticity cannot be
accurately determined and are likely to change during
the working life of the device.
All of the supporting frames, with the exception of
the NaviGate Cardiac Structures, are self-expanding
structures made of nitinol. This is a near-equiatomic
Ni–Ti alloy that exhibits enhanced recoverable elastic
strains up to 8% (about 20 times larger than for
stainless steel), commonly referred to as super-elastic
behavior. Thanks to this property, the valves are
delivered after crimping them inside a covering sheath,
which is then pulled back once the prostheses have
reached the anatomical site. This allows the frames to
re-expand towards their unstressed conﬁgurations. The
self-expanding approach provides the ability to better
adapt to geometrical changes that may occur in the
implantation site during the valve life.
In the case of the NaviGate Cardiac Structures the
frame is made from a balloon-expandable Co–Cr alloy.
During the implantation, the valve is collapsed around
an empty balloon with a crimping device, which plas-
tically deforms the frame by producing plastic hinges.
The valve is then re-deformed to the expanded con-
ﬁguration by inﬂating the balloon with a liquid solu-
tion. Balloon-expandable approaches allow the
TABLE 1. Representation of the devices known at a most advanced stage of development and description of their main features.
CARDIAQ PROSTHESIS 
CardiAQ Valve Technologies Inc., Winchester, Massachusetts, US 
Frame: self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed porcine pericardium  
Anchoring: atrial & ventricular flanges (Fig. 1.c) 
Delivery: Transseptal/Transapical (Fig. 2.a/b) 
Trials: first-in-human in 2012 
CARDIOVALVE 
Valtech Cardio Ltd, Or Yehuda, Israel 
Frame: self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial flange (full details not currently available)  
Delivery: not specified 
Trials: animals only 
DOUBLE-CROWNED MITRAL VALVE IMPLANTATION 
Zhejiang University, Hangzhou, China & CHUV, Lausanne, Switzerland 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Porcine pulmonary & aortic homografts  
Anchoring: atrial & ventricular flanges (Fig. 1.c) 
Delivery: Left atriotomy (Fig. 2.c) 
Trials: animals only 
ENDOVALVE 
Micro Interventional Devices, Langhorne, Pennsylvania, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: Arrow-head anchors 
Delivery: Transapical (Fig. 2.b) 
Trials: animals only 
FORTIS 
Edwards Lifesciences 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed bovine pericardium  
Anchoring: atrial flange and native valve anchors (Fig. 1.b) 
Delivery: Transapical (Fig. 2.b) 
Trials: first-in-human in 2014 
GORMAN 
The Trustees of The University of Pennsylvania, Philadelphia, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial & ventricular flanges (Fig. 1.c) 
Delivery: Left atriotomy (Fig. 2.c) 
Trials: animals only
HIGHLIFE 
HighLife Medical Inc., California, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial & ventricular flanges (Fig. 1.c) 
Delivery: Left atriotomy (Fig. 2.c) 
Trials: animals only 
MEDTRONIC TRANSCATHETER MITRAL VALVE  
Medtronic Inc., Minneapolis, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial flange & native valve anchors (Fig. 1.b) 
Delivery: Left atriotomy (Fig. 2.c) 
Trials: animals only 
MITRALSEAL 
Avalon Medical Ltd., Stillwater, Minneapolis, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial flange & ventricular tethers (Fig. 1.a) 
Delivery: Transapical (Fig. 1.b) 
Trials: animals only 
MITRASSIST 
MitrAssist Medical Ltd, Misgav, Israel 
Frame: superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial flange & native valve anchors (Fig. 1.b) 
Delivery: Not specified 
Trials: animals only 
MIVAR 
Trinity College Dublin, EIRE 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial cage (Fig. 1.e) 
Delivery: Not specified 
Trials: animals only
NAVIGATE CARDIAC STRUCTURES 
NaviGate Cardiac Structures Inc., Cleveland, Ohio, US 
Frame: Balloon expandable, made of cobalt chromium alloy 
Leaflets: Glutaraldehyde fixed pericardium  
Anchoring: atrial & ventricular flanges (Fig. 1.c)  
Delivery: Transseptal (Fig. 1.a) 
Trials: none currently reported
TENDYNE 
Tendyne Medical Inc., Baltimore, Maryland, US 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed bovine pericardium  
Anchoring: atrial flange & ventricular tethers (Fig. 1.a) 
Delivery: Transapical (Fig. 2.b) 
Trials: first-in-human in 2013 
TIARA
NeoVasc Inc., Richmond, British Columbia, Canada 
Frame: Self-expandable, made of superelastic Ni-Ti alloy 
Leaflets: Glutaraldehyde fixed bovine pericardium  
Anchoring: atrial flange and native valve anchors (Fig. 1.b) 
Delivery: Transapical (Fig. 1.b) 
Trials: first-in-human in 2013
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operator to administer the deployment pressure, but in
the case of the mitral valve they require particular care
to avoid excessive deformation of the aortic valve.
Moreover, they are typically less suitable for the
implementation of retrievable procedures.
Anchoring Approach
The anchoring methods required for percutaneous
mitral valves are distinct from those used in TAVI
devices, due to the more irregular and dynamic mor-
phology. In fact, the substantial amount of calcium
present in a stenotic native aortic valve can generate
the large radial reaction forces that are commonly used
to ﬁx aortic prostheses. In the case of the mitral valve,
the stiﬀening mineral is normally insuﬃcient to pro-
vide radial forces able to secure the device. Moreover,
high levels of radial forces would not be advisable, as
they could cause left ventricular outﬂow obstruction
(LVOTO)18 due to the native anterior leaﬂet being
pushed radially into the LVOT, as well as possible
aortic valve impairment, due to the device extending
into the aorto-mitral curtain.51
Hence, anchoring in percutaneous mitral valves is
commonly achieved by application of counteracting
axial forces, tensioning the device between a proximal
and a distal constraints. In the case of the Tendyne and
MitralSeal the proximal constraint is represented by a
ﬂange, which lies ﬂat against the atrial surface of the
native mitral annulus, while the valve is ﬁxed distally
to the apex of the left ventricle, through a set of ten-
sioned threads (Fig. 1a). Although these threads look
similar to chordae tendineae, they have the function to
anchor the frame, with no direct action on the valve
leaﬂets. This solution may contribute to the reduction
of paravalvular leakage (PVL), thanks to the presence
of the atrial ﬂange pressed on the inlet wall. A
potential drawback might be represented by possible
variations in the tension applied to the distal threads in
the event of left ventricle remodelling.
An alternative approach is adopted in the FORTIS,
Gorman, Medtronic, MitrAssist, and Tiara, which in-
stead of threads use ventricular distal anchors that
grasp the free margins of the native leaﬂets (Fig. 1b).
The Fortis is secured by two ventricular tabs that
capture the aortic and mural leaﬂets, combined with an
atrial ﬂange. The Gorman valve is secured using upper
and lower wire-weave ﬂanges. The Tiara uses ventric-
ular tabs that capture the aortic and mural leaﬂets,
combined with three atrial ﬂanges that anchor the
device on the right and left ﬁbrous trigones and native
posterior leaﬂet. An additional feature of the Tiara
anchoring system is its saddle-shape, designed to better
conform the native annulus.31 However, this makes the
implantation of the device more challenging, as the
saddle shaped device demands accurate orientation. A
potential advantage of clamping the native leaﬂets
could derive by reducing the risk of LVOTO, though
the long-term effect of the force acting on the subval-
vular components still needs to be ascertained.45
The Double-Crowned Mitral Valve and the HighLife
adopt clamping mechanisms that engage with the
upstream and downstream sides of the mitral annulus,
reducing the interaction with the subvalvular appara-
tus (Fig. 1c). This is achieved by squeezing the mitral
annulus between two Z-stents. The deployment of the
Double-Crowned Mitral Valve Implantation requires
the presence of an annuloplasty ring in the mitral
annulus, thus making its application limited to only a
sub-set of patients. The HighLife relies on the align-
ment of a groove with the annulus to anchor the device
and provide a seal between the left atrium and the
ventricle. The same securing principle is used by the
CardiAQ Prosthesis, Cardiovalve and NaviGate Car-
diac Structures, which incorporate two sets of barbs or
‘wings’ protruding from the main body to improve the
grasp. The advantage of this approach is a reduced
interference with the subvalvular apparatus, which
avoids potential issues associated with re-modeling.
However, the solution does not prevent LVOTO, and
FIGURE 1. Percutaneous mitral valve anchoring systems. (a) Atrial flange and ventricular tethers, (b) atrial flange and native valve
anchors, (c) atrial and ventricular flanges, (d) subannular hooks, and (e) atrial cage.
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the presence of barbs may represent a risk for sur-
rounding structures such as the coronary sinus.
In the case of the Endovalve, ﬁxation of the device is
provided by a series of anchors around the edge of the
valve, consisting of a solid core and ﬂexible barb
(Fig. 1d). The ﬂexible barb hugs the core, thereby
enabling the anchors to pierce the mitral valve tissue as
the device is deployed. Once inserted inside the tissue,
the barb springs away from the core, forming an
arrowhead which prevents retraction and ensures that
the anchors do not disengage. This anchoring method
could be effective in preventing PVL, but it does not
facilitate multiple deployment or retrieval of the
device. Therefore, incorrect release of the device would
foreseeably require open-heart surgery.
An alternative approach is provided by the MiVAR
valve, which relies on an atrial ﬁxation system (Fig. 1e);
based on a nitinol cage that conforms to the atrial
chamber, preventing axial displacement of the valve. A
potential disadvantage of this design is that, each time
the left ventricle contracts, the associated apical-basal
motion30 and pressure gradient may cause the device to
move relative to the wall of the left atrium, the conse-
quences of which are to be determined. This solution
makes the valve operation totally independent from
any remodelling that may occur to the subvalvular
apparatus or left ventricle, and could help to reduce
PVL. Though, the presence of the anchoring cage could
impair the atrial function, as well as the aortic valve.
Prevention of Regurgitation
Contrary to standard surgical valves, which are
normally sutured onto the aortic annulus (after dis-
section of the native leaﬂets), transcatheter valves are
expanded into the diseased valve leaﬂets. This may
result in the presence of gaps between the prosthesis and
the surrounding native tissues, with consequent PVL.
PVL has been identiﬁed as a major shortcoming of
TAVI, and its impact is potentially more prominent in
the mitral position due to the higher transvalvular
pressure diﬀerence.17 Therefore it is of paramount
importance that any leakage around the edge of the
device is actively mitigated with speciﬁc design solu-
tions. Most of the devices, including the Cardiovalve,
Endovalve, FORTIS, HighLife, Medtronic, Mitraseal,
Tendyne andTiara, prevent PVL by using a fabric ﬂange
sutured onto the aortic portion of the metal frame. A
unique method is employed by theGorman valve, which
relies on the ﬂexibility of a nitinol wire-weave stent body
to conform to the complex host geometry and create a
seal. The CardiAQ Prosthesis, Double-Crowned Mitral
Valve,MitrAssist, NaviGate andMiVAR do not report
any speciﬁc measure taken to mitigate PVL.
Delivery
TMVI need to conform to the irregular anatomy of
the site and larger oriﬁces than TAVI. This requires
more material for the valve components, which trans-
lates into larger diameters of the collapsed device and
wider access routes.
With suﬃciently low valve proﬁles, endovascular
retrograde approach allows to conveniently reaching
the aortic valve from the femoral vein, after puncturing
of the inter-atrial septum (Fig. 2a). This approach has
been very popular in the early experience with TAVI
devices, because the larger dimensions and greater
elasticity of the veins allows the passage of relatively
large collapsed stents. In the case of the mitral valve,
this is the most favorable access, because it does not
require navigation through the subvalvular apparatus.
However, this procedure requires the device to ﬁt in-
side a catheter equal or smaller than 24 F (8 mm
diameter), while current valves still require relatively
larger catheters of 30–33 Fr (10–11 mm diameter),
with the exception of the MitrAssist, for which a
delivery system diameter of 18 Fr (6 mm diameter) is
declared. Currently, only three of the devices have
achieved a percutaneous delivery; CardiAQ Prosthesis,
FIGURE 2. Percutaneous mitral valve delivery. (a) Transseptal, (b) transapical, (c) left atriotomy, and (d) Transaortic.
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NaviGate Cardiac Structures and MiVAR, all but the
later use a transseptal approach.16
The transapical route (Fig. 2b), widely used for the
implantation of aortic valves, allows the passage of
larger valves; and therefore is currently the most
adopted approach. However, access to the mitral valve
requires navigating the delivery system through the
subvalvular apparatus. To prevent the device becom-
ing entangled in the chordae tendineae, expert inter-
pretation of the ﬂuoroscopic and transesophageal
echocardiographic guidance (TEE) is required. Despite
this challenge, the transapical approach has been used
for implanting the CardiAQ Prosthesis, FORTIS and
Tiara4 and is necessary for the anchoring systems of
the Tendyne, MitralSeal and Endovalve.
A left atriotomy (Fig. 2c) is required to implant the
Double-Crowned Mitral Valve Implantation, Gorman,
HighLife and Medtronic valves. This approach
involves an incision of approximately 10 cm, making it
the most invasive access for transcatheter valves
implantation.
A unique choice of surgical approach is adopted for
the MitrAssist, which currently uses a transaortic
implant (Fig. 2d) where a minimally invasive surgical
incision into the aorta is made to insert the device.
In vivo Evaluation
Evaluation of transcatheter prosthetic mitral valves
in large animals has been reported for the CardiAQ
Prosthesis, Cardiovalve, Double-Crowned Mitral Valve
Implantation, Endovalve, FORTIS, Gorman, HighLife,
Medtronic, MitrAssist, Tendyne and Tiara, simi-
larly indicating that the approach is feasible and
promising, whilst highlighting their current deﬁcien-
cies.3,4,16,23,27,37,55 A common failure mode of the
devices was inadequate anchoring mechanisms, result-
ing in device migration, which was also one of the main
causes of LVOTO.However some of these failuremodes
may be due to inappropriate sizing. For example, the
relatively high rate of PVL in the chronic in animal
evaluation of the Tiara was attributed to only one size
device being available for the range of native valves.16
The MitralSeal is routinely employed for veterinary
applications in dogs, which are characterized by similar
mitral valve pathologies to humans.44
Generally, in animal experience with TMVIs indi-
cate that the current devices require substantial design
improvements, namely to position and anchor the
devices. These improvements may partly be achieved
by developing appropriate algorithms for selecting the
size of the device to be implanted for a particular
native valve. For the Tiara device, implants in human
cadavers are reported,4 which demonstrated appro-
priate geometric positioning.
In human evaluation of minimally invasive mitral
valve replacements has mainly occurred in the last
couple of years. In 2012, the CardiAQ prosthesis was
the ﬁrst to be implanted in a human, followed by the
Tendyne in 2013, and the Tiara and FORTIS in 2014.
The Cardiovalve, Double-Crowned Mitral Valve
Implantation, Endovalve, Gorman, HighLife, Medtron-
ic, MitrAssist and MiVAR all remain in animal trials,
whilst no in vivo data are reported for the NaviGate
Cardiac Structures yet.
The ﬁrst-in-man experience of the CardiAQ Pros-
thesis was performed by the team of Lars Søndergaard
at the Heart Centre in Copenhagen, Denmark, in June
2012. The valve was implanted into an 86-year-old
high-risk patient suffering from severe MR. The device
successfully alleviated the patient’s severe regurgita-
tion, although some remained and 3 days later the
patient died from multi-organ failure.49
In the following year two Tendyne valves were
implanted at the French Hospital in Asuncion, Para-
guay.16 They were successful in reducing the MR grade
from IV to a grade I in one patient and completely
eliminated it in the other.
The Tiara was implanted into two patients at St.
Paul’s Hospital, Vancouver, British Columbia,
Canada16 at the beginning of 2014 and successfully
eliminated MR as well as achieving improved LV
stroke volumes.
Later in 2014, a total of ﬁve FORTIS valves were
implanted, four by the Heart Team at St. Thomas’
Hospital in London, UK and one at St Michael’s
Hospital in Toronto, Canada.5 The patients had pre-
sented with severe mitral valve disease and showed
promising initial recovery after the implantation of
FORTIS, although 3 of the patients died between 4
and 76 days after the procedure. Failure modes and
causes of death have not been reported.
The human trials have demonstrated the potential
of TMVIs to diminish MR to a similar level achieved
by surgical replacements, however the long term follow
up of these implantations is still on going.
REGULATORY ISSUES
Prior to reaching the market, the safety and eﬃcacy of
any prospective heart valve substitutemust be ascertained
by means of in vitro and in vivo investigations. Guidelines
and recommendations for the qualiﬁcation of the design
and manufacture of permanent prosthetic valve devices
are provided by the International Standards ISO
5840—Cardiovascular implants—Cardiac valve prosthe-
ses. This imposes the design and minimum performance
speciﬁcations for aortic andmitral valves, andoutlines the
approach required to assess the properties of the
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prostheses and their materials, and those for the in vivo
evaluation. The standard, ﬁrst enforced in 1984 and ini-
tially based on a ‘requirement based’ approach, has re-
cently adopted a ‘risk based’ approach (ISO 5840:2005),
more in line with FDA guidance and better suited for the
recent transformative developments of the technologies.
The substantial technological and functional differences
between surgical and minimally invasive valve prostheses
have driven the drafting and publication of an additional
updated part of the standard, ISO 5840-3:2013, speciﬁ-
cally created for the qualiﬁcation of transcatheter heart
valve substitute and valid since March 2013.
Most of the speciﬁcations and assessment
approaches described in the International Standards
ISO 5840:2005 and ISO 5840-3:2013 are applicable to
minimally invasive mitral valve replacements. How-
ever, as they are based on the existing clinical evidence,
mainly available only for surgical valves and TAVI,
revision may be needed to better address this emerging
class of devices.
Diastolic Performance
The current standards prefer the measurement of
the eﬀective oriﬁce area (EOA) to assess the hydro-
dynamic performance of valves, during the forward
ﬂow phase (diastolic phase for the mitral valve).
However, due to its larger oriﬁce, the EOA is a less
critical parameter for the healthy function of the mitral
valve compared to the aortic valve, and is often sac-
riﬁced in favor of better leaﬂet coaptation. For exam-
ple, in the edge-to-edge repair technique, the EOA of
the mitral valve can be reduced by as much as 60%,
without detrimental consequences. Therefore, assess-
ment based on the eﬀective surface area using the
proximal isovelocity surface area (PISA) method34,46
may be more relevant for the intraoperative (and
in vitro) evaluation of mitral devices.
Systolic Performance
The performance of the valve during the closing and
closed phase is veriﬁed and controlled by limiting the
regurgitant fraction. The ISO 5840-3:2013 acknowl-
edges the inevitability of higher degrees of paravalvular
leakage in transcatheter devices, accepting larger
regurgitant fractions (up to 25% at a CO of 5 L/min,
for large sizes) than for corresponding surgical valves.
This is compensated by more severe demands in terms
of EOA.
As discussed above, though this approach is
acceptable for TAVIs, in the case of the mitral valve,
increases in EOA would possibly be unnecessary and
insuﬃcient to compensate signiﬁcant levels of leakage,
which should instead be mitigated.
Risk Management Aspects
The potential hazards, associated failure modes and
subsequent evaluation methods currently described in
the ISO 5840-3:2013 (Annex G) are deﬁned based on
the TAVI experience. In order to better reﬂect the
lesson learnt from current in vivo experiences with
TMVI, the risks associated with unintended anatomi-
cal interactions should also consider failure modes
such as: left ventricular out ﬂow tract obstruction
(LVOTO), which can lead to heart failure and death;
left circumﬂex (LCx) artery compression, which would
inhibit the blood supply to the posterolateral left
ventricle and anterolateral papillary muscle; and cor-
onary sinus (CS) compression, which would hinder the
deoxygenated blood ﬂow from the heart muscles to the
right atrium.
Animal Evaluation
The use of animal models to evaluate TAVI devices
has severe limitations. As stated in the ISO 5840-
3:2013, the soft nature of the tissue present in the
animals’ aortic valve is not representative of the stiﬀer
calciﬁed aortic valves that would be present in typical
human patients. As a result, preclinical in vivo tests
cannot assess the migration of TAVI solutions. How-
ever, the softer anatomical site is arguably more rep-
resentative of a regurgitant mitral valve, and therefore
the function of animal evaluation for TMVIs should
include assessment of migration of the devices. This
will require a more strict identiﬁcation of representa-
tive animal sizes, in order to ensure that the implants
provide the most signiﬁcant information.
DISCUSSION AND CONCLUSION
After the rapid development of pulmonary and
aortic transcatheter heart valve implantations, the
advantages of percutaneous procedures are ﬁnally
being transferred to the functional replacement of the
mitral valve. The experience gained with TAVI devices
is resulting fundamental in the development of this
approach, which though presents unique challenges
requiring new technical solutions, due to the more
complex morphology and function of the mitral valve.
Similarly to the ﬁrst generation of percutaneous
aortic valve, PVL and embolization remain major
hurdles, whose impact is ampliﬁed by the more severe
transvalvular pressures and valve dynamics. The
accuracy of medical imaging technologies and sizing
criteria will play a major role in reducing these com-
plications, by allowing the selection of the most suit-
able TMVI for each patient. In fact, for a correct
ﬁtting, most of the valves under development require
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proper geometrical matching with the irregular mitral
annulus (normally characterized by an asymmetric
bean-shape proﬁle, laying on a saddle-shape surface),
as well as the subvalvular structures and the heart
chambers. All these components are characterized by
signiﬁcant variations of their dimensions during the
cardiac cycle, due to the dynamic nature of the mitral
valve apparatus and surrounding anatomy. Therefore,
for each prosthetic valve, it is essential to identify what
parameters are the most relevant for ensuring proper
anchoring and sealing. Accurate and comprehensive
sizing algorithms will need to be developed, to ensure
the safety and proper functionality of TMVIs. This will
necessarily require continuous revision and reﬁning,
based on the in vivo experience.
Future designs will also need to focus on reducing
the collapsed proﬁle of the device, enabling a truly
endovascular access. This will foreseeably follow the
developmental trend that has characterized aortic
solutions, which have achieved substantial advances in
reducing the size of the loaded valve and delivery
system, oﬀering now alternative implantation
approaches with reduced vascular injury. An impor-
tant feature to inherit from the latest generation of
TAVI will be the ability to reposition the valve during
the implantation procedure. In fact, as most of the
anchoring approaches adopted for the mitral applica-
tion require a precise axial and angular positioning,
inappropriate release is more likely to lead to func-
tional complications and increased PVL.
Concerns about safety and durability in the func-
tionally more stressed mitral position will be relieved
only after medium and long term clinical outcome, but
the positive results of TAVI devices suggest that metal
frames can be suitable to withstand heavy loading
conditions. Also, as for TAVI, transcatheter mitral
valves might result into a high rate of silent cerebral
ischemic lesions. These, in fact, appear to be indepen-
dent from catheter manipulation or the severity of
calciﬁcation, and possibly associated with the hemo-
dynamic disturbance produced by the valve-in-valve
conﬁguration.19
In order to be established as a sustainable therapy, it
is essential that transcatheter mitral valve replacement
fully demonstrates its safety and eﬃcacy, guaranteeing
at the same time aﬀordable costs. In fact, contrary to
TAVI devices, which only compete with other
replacement strategies, mitral valves will have to
operate in a more aggressive commercial climate,
contending the role to a range of surgical and trans-
catheter, replacement and repair solutions, with vari-
ous degrees of invasivity. However it can be envisaged
that, similarly to what has happened for aortic valve
therapies, also currently established mitral treatments
will strongly beneﬁt from the novel technical solutions
developed for TMVI. In fact, the dimensional reduc-
tion of the supportive structure of the leaﬂets and the
availability of collapsible sutureless mitral valves may
contribute to the development of safer and less invasive
surgical applications.
In conclusion, ﬁrst experiences with transcatheter
mitral valve replacement have been very encouraging,
demonstrating the feasibility and the potential beneﬁt
of the approach. Undoubtedly, substantial progresses
will be needed in order to overcome current limitations
and establish this solution as a competitive treatment.
The process will have to be assisted by regulatory
standards that better reﬂect the speciﬁc clinical needs
and the recent experiences with this approach.
ACKNOWLEDGMENTS
This work has been supported by the British Heart
Foundation, UK ‘‘Development of an artiﬁcial mitral
valve for transcatheter implant’’ and by an anonym
philanthropic donation sponsoring Georgia Preston-
Maher’s Studentship.
CONFLICT OF INTEREST
Miss Georgia L. Preston-Maher, Dr Ryo Torii and
Dr Gaetano Burriesci declare that they have no conﬂict
of interest.
HUMAN AND ANIMAL STUDIES
No human or animal studies were carried out by the
authors for this article.
OPEN ACCESS
This article is distributed under the terms of the
Creative Commons Attribution License which permits
any use, distribution, and reproduction in any med-
ium, provided the original author(s) and the source are
credited.
REFERENCES
1Alﬁeri, O., F. Maisano, M. De Bonis, P. L. Stefano, L.
Torracca, M. Oppizzi, et al. The double-oriﬁce technique in
mitral valve repair: a simple solution for complex prob-
lems. J. Thorac. Cardiovasc. Surg. 122(4):674–681, 2001.
2Axford, J., and C. O’Callaghan. Medicine. Malden, MA:
Blackwell Science, 2004.
3Banai, S., E. M. Jolicoeur, M. Schwartz, P. Garceau, S.
Biner, J. F. Tanguay, et al. Tiara: a novel catheter-based
mitral valve bioprostheses—initial experiments and short-
Minimally Invasive Mitral Valve Replacements
term pre-clinical results. J. Am. Coll. Cardiol. 60(15):1430–
1431, 2012.
4Banai, S., S. Verheye, A. Cheung, M. Schwartz, A. Marko,
R. Lane, et al. Transapical mitral implantation of the Tiara
bioprostheses. JACC Cardiovasc. Interv. 7(2):154–162,
2014.
5Bapat, V., L. Buellesfeld, M. D. Peterson, J. Hancock, D.
Reineke, C. Buller, et al. Transcatheter mitral valve
implantation (TMVI) using the Edwards FORTIS device.
EuroIntervention 10(U):120–128, 2014.
6Block, P. C. Percutaneous mitral valve repair: are they
changing the guard? Circulation 111(17):2154–2156, 2005.
7Block, P.,H.Hermann, and P.Whitlow. Percutaneous edge-
to-edge mitral valve repair using the Evalve MitraClip: ini-
tial experience with functional mitral regurgitation in the
EVEREST I trial. J. Am. Coll. Cardiol. 47(4):283A, 2006.
8Block, P. C., and I. F. Palacios. Clinical and hemodynamic
follow-up after percutaneous aortic valvuloplasty in the
elderly. Am. J. Cardiol. 62(10):760–763, 1988.
9Bonhoeffer, P., Y. Boudjemline, Z. Saliba, J. Merckx, Y.
Aggoun, D. Bonnet, et al. Percutaneous replacement of
pulmonary valve in a right-ventricular to pulmonary-artery
prosthetic conduit with valve dysfunction. Lancet
356(9239):1403–1405, 2000.
10Chiam, P. T., and C. E. Ruiz. Percutaneous transcatheter
mitral valve repair: a classiﬁcation of the technology. JACC
Cardiovasc. Interv. 4(1):1–13, 2011.
11Claramunt, R., J. M. Garcı´a Pa´ez, L. Alvarez, A. Ros, and
M. C. Casado. Fatigue behaviour of young ostrich peri-
cardium. Mater. Sci. Eng. C 32(6):1415–1420, 2012.
12Coats, L., and P. Bonhoeffer. New percutaneous treat-
ments for valve disease. Heart 93(5):639–644, 2007.
13Cohn, L. H. Minimally invasive valve surgery. J. Card.
Surg. 16(3):260–265, 2001.
14Davidson, M. J., and D. S. Baim. Percutaneous aortic valve
interventions. In: Cardiac Surgery in the Adult, edited by
L. H. Cohn. New York: McGraw-Hill, 2008, pp. 963–971.
15Davidson, M. J., J. K. White, and D. S. Baim. Percuta-
neous therapies for valvular heart disease. Cardiovasc.
Pathol. 15(3):123–129, 2006.
16De Backer, O., N. Piazza, S. Banai, G. Lutter, F. Maisano,
H. C. Herrmann, et al. Percutaneous transcatheter mitral
valve replacement. An overview of devices in preclinical
and early clinical evaluation. Circ. Cardiovasc. Interv.
7(3):400–409, 2014.
17De Bonis, M., E. Lapenna, R. Lorusso, N. Buzzatti, S.
Gelsomino, M. Taramasso, et al. Very long-term results
(up to 17 years) with the double-oriﬁce mitral valve repair
combined with ring annuloplasty for degenerative mitral
regurgitation. J. Thorac. Cardiovasc. Surg. 144(5):1019–
1024, 2012.
18Ducas, R. A., D. S. Jassal, S. R. Zieroth, I. D. Kirkpatrick,
and D. H. Freed. Left ventricular outﬂow tract obstruction
by a bioprosthetic mitral valve. Diagnosis by cardiac com-
puted tomography. J. Thorac. Imaging 24(2):132–135, 2009.
19Ducci, A., S. Tzamtzis, M. J. Mullen, and G. Burriesci.
Hemodynamics in the Valsalva sinuses after transcatheter
aortic valve implantation (TAVI). J. Heart Valve Dis.
22(5):688–696, 2013.
20Edwards, M. B., and K. M. Taylor. Outcomes in nonage-
narians after heart valve replacement operation. Ann.
Thorac. Surg. 75(3):704–708, 2003.
21Feldman, T., H. S. Wasserman, H. C. Herrmann, W. Gray,
P. C. Block, P. Whitlow, et al. Percutaneous mitral valve
repair using the edge-to-edge technique: six-month results
of the EVEREST phase I clinical trial. J. Am. Coll. Cardiol.
46(11):2134–2140, 2005.
22Ghanbari, H., H. Viatge, A. G. Kidane, G. Burriesci, M.
Tavakoli, and A. M. Seifalian. Polymeric heart valves: new
materials, emerging hopes. Trends Biotechnol. 27(6):359–
367, 2009.
23Gillespie, M. J., M. Minakawa, M. Morita, M. Vergnat, K.
J. Koomalsingh, J. D. Robb, et al. Sutureless mitral valve
replacement: initial steps towards a percutaneous proce-
dure. Ann. Thorac. Surg. 96(2):670–674, 2013.
24Helton, T. J., S. R. Kapadia, and E. M. Tuzcu. Clinical
trial experience with transcatheter aortic valve insertion.
Int. J. Cardiovasc. Imaging. 27(8):1143–1154, 2011.
25Herrmann, H. C. Transcatheter mitral valve implanta-
tion—The advantage of MIS-tMVI may make it the ideal
choice for high-risk patients. Cardiac Interventions Today.
2009. August/September, Cover Story.
26Herrmann, H. C., S. Kar, R. Siegel, P. Fail, C. Loghin, S.
Lim, et al. Effect of percutaneous mitral repair with the
MitraClip device on mitral valve area and gradient. Euro-
intervention 4(4):437–442, 2009.
27Iino, K., J. Boldt, L. Lozonschi, A. Metzner, J. Schoettler,
R. Petzina, et al. Off-pump Transapical mitral valve
replacement: evaluation after one month. Eur. J. Cardio-
thorac. Surg. 41(3):512–517, 2012.
28Inoue, K., T. Owaki, T. Nakamura, F. Kitamura, and N.
Miyamoto. Clinical-application of transvenous mitral
commissurotomy by a new balloon catheter. J. Thorac.
Cardiovasc. Surg. 87(3):394–402, 1984.
29Iung, B., G. Baron, E. G. Butchart, F. Delahaye, C.
Gohlke-Ba¨rwolf, O. W. Levang, et al. A prospective survey
of patients with valvular heart disease in Europe: the euro
heart survey on valvular heart disease. Eur. Heart J.
24(13):1231–1243, 2003.
30Iung, B., B. Cormier, P. Ducimetie`re, J. M. Porte, O.
Nallet, P. L. Michel, et al. Immediate results of percu-
taneous mitral commissurotomy. A predictive model on a
series of 1514 patients. Circulation 94(9):2124–2130, 1996.
31Jensen, M. O., A. A. Hage`ge, Y. Otsuji, and R. A. Levine.
The unsaddled annulus: biomechanical culprit in mitral
valve prolapse? Circulation 127(7):766–768, 2013.
32Kaye, D. M., M. Byrne, C. Alferness, and J. Power.
Feasibility and short-term efﬁcacy of percutaneous
mitral annular reduction for the therapy of heart failure-
induced mitral regurgitation. Circulation 108(15):1795–
1797, 2003.
33Ko¨rfer, R., U. Schu¨tt, K. Minami, D. Hartmann, H.
Ko¨rtke, and J. U. Lu¨th. Left ventricular function in heart
valve surgery: a multidisciplinary challenge. J. Heart Valve
Dis. 4(2):S194–S197, 1995.
34Lancellotti, P., L. Moura, L. A. Pierard, E. Agricola, B. A.
Popescu, C. Tribouilloy, et al. European association of
echocardiography recommendations for the assessment of
valvular regurgitation. Part 2: mitral and tricuspid regur-
gitation (native valve disease). Eur. J. Echocardiogr.
11(4):307–332, 2010.
35Liddicoat, J. R., B. D. Mac Neill, A. M. Gillinov, W. E.
Cohn, C. H. Chin, A. D. Prado, et al. Percutaneous mitral
valve repair: a feasibility study in an ovine model of acute
ischemic mitral regurgitation. Catheter Cardiovasc. Interv.
60(3):410–416, 2003.
36Lloyd-Jones, D., R. J. Adams, T. M. Brown, M. Carne-
thon, S. Dai, G. De Simone, et al. Heart disease and stroke
statistics 2010 update: a report from the American heart
association. Circulation 121(7):46–215, 2010.
PRESTON-MAHER et al.
37Ma, L., P. Tozzi, C. H. Huber, S. Taub, G. Gerelle, and L.
K. von Segesser. Double-crowned valved stents for off-
pump mitral valve replacement. Eur. J. Cardiothorac. Surg.
28(2):194–199, 2005.
38Masson, J. B., J. Kovac, G. Schuler, J. Ye, A. Cheung, S.
Kapadia, et al. Transcatheter aortic valve implantation
review of the nature, management, and avoidance of pro-
cedural complications. JACC Cardiovasc. Interv. 2(9):811–
820, 2009.
39Mckay, R. G. The mansﬁeld scientiﬁc aortic valvuloplasty
registry—overview of acute hemodynamic-results and
procedural complications. J. Am. Coll. Cardiol. 17(2):485–
491, 1991.
40Mirabel, M., B. Iung, G. Baron, D. Messika-Zeitoun, D.
De´taint, J. L. Vanoverschelde, et al. What are the charac-
teristics of patients with severe, symptomatic, mitral
regurgitation who are denied surgery? Eur. Heart J.
28(11):1358–1365, 2007.
41Modi, P., A. Hassan, and W R Jr Chitwood. Minimally
invasive mitral valve surgery: a systemic review and meta-
analysis. Eur. J. Cardiothorac. Surg. 34(5):943–952, 2008.
42Nkomo, V. T., J. M. Gardin, T. N. Skelton, J. S. Gottdi-
ener, C. G. Scott, and M. Enriquez-Sarano. Burden of
valvular heart diseases: a population-based study. Lancet
368(9540):1005–1011, 2006.
43Osnabrugge, R. L., A. P. Kappetein, M. R. Reynolds, and
D. J. Cohen. Cost-effectiveness of transcatheter valvular
interventions: economic challenges. Eurointervention 9:48–54,
2013.
44Pedersen, H. D., and J. Ha¨ggstro¨m. Mitral valve prolapse
in the dog: a model of mitral valve prolapse in man. Car-
diovasc. Res. 47(2):234–243, 2000.
45Rabbah, J. P., N. Saikrishnan, A. W. Siefert, A. Santhan-
akrishnan, and A. P. Yoganathan. Mechanics of health and
functionally diseased mitral valves: a critical review. J.
Biomech. Eng. 135(2):021007, 2013.
46Recusani, F., G. S. Bargiggia, A. P. Yoganathan, A.
Raisaro, L. M. Valdes-Cruz, H. W. Sung, et al. A new
method for quantiﬁcation of regurgitant ﬂow-rate using
color doppler ﬂow imaging of the ﬂow convergence region
proximal to a discrete oriﬁce: an in vitro study. Circulation
83(2):594–604, 1991.
47Roques, F., S. A. Nashef, P. Michel, E. Gauducheau, C. de
Vincentiis, E. Baudet, et al. Risk factors and outcome in
European cardiac surgery: analysis of the EuroSCORE
multinational database of 19030 patients. Eur. J. Cardio-
thorac. Surg. 15(6):816–823, 1999.
48Siminiak, T., L. Firek, O. Jerzykowska, P. Kałmucki, M.
Wołoszyn, P. Smuszkiewicz, et al. Percutaneous valve
repair for mitral regurgitation using the Carillon Mitral
Contour System. Description of the method and case
report. Kardiol. Pol. 65(3):272–279, 2007.
49Sondergaard, L. Transcatheter Mitral Valve Implantation:
CardiAQ. Presented at TCT 2012, Miami, Florida, US, 22–
26 Oct 2012.
50Taramasso, M., M. Cioni, A. Giacomini, I. Michev, C.
Godino, M. Montorfano, et al. Emerging approaches of
transcatheter valve repair/insertion. Cardiol. Res. Pract.
2010:540749, 2010.
51Timek, T. A., G. R. Green, F. A. Tibayan, D. T. Lai, F.
Rodriguez, D. Liang, et al. Aorto-mitral annular dynamics.
Ann. Thorac. Surg. 76(6):1944–1950, 2003.
52US Census Bureau. Statistical Abstract of the US: 2006,
Table 12.
53Vahanian, A., and I. F. Palacios. Percutaneous approaches
to valvular disease. Circulation 109(13):1572–1579, 2004.
54Zajarias, A., and A. G. Cribier. Outcomes and safety
of percutaneous aortic valve replacement. J. Am. Coll.
Cardiol. 53(20):1829–1836, 2009.
55Zou, Y., E. Ferrari, and L. K. von Segesser. Off-pump
transapical mitral valve-in-ring implantation. Eur. J.
Cardiothorac. Surg. 43(4):849–855, 2013.
Minimally Invasive Mitral Valve Replacements
